Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation
(1 available);
any
Irf1 mutation
(19 available)
|
|
|
mortality/aging
|
|
• increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls
• treatment with recombinant IL12 significantly improves survival of MNU treated mice
|
homeostasis/metabolism
immune system
|
|
• impairment in the ability to produce IFNG in response to Con A stimulation
• IL12 treatment can rescue the impairment in IFNG production
|
|
|
• by lymphocytes following Con A stimulation
• IL12 treatment can rescue the impairment in IFNG production
|
neoplasm
|
|
• following a single dose of MNU most mice develop massive lymphoid neoplasias
• treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice
|
|
|
• following a single dose of MNU compared to similarly treated wild-type controls
|
hematopoietic system
|
|
• impairment in the ability to produce IFNG in response to Con A stimulation
• IL12 treatment can rescue the impairment in IFNG production
|
Allelic
Composition |
Irf1tm1Mak/Irf1tm1Mak
|
|
Genetic
Background |
either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2) |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation
(1 available);
any
Irf1 mutation
(19 available)
|
|
|
hematopoietic system
|
|
• CD8+/CD4+ T cell ratio is lower than wild-type or Irf2-deficient mice during course of LCMV infection
|
|
|
• numbers are normal or slightly increased in thymi
|
|
|
• CD4+CD8- T cells are often but not always increased in number in homozygotes
|
|
|
• 10-fold reduction in TCR alpha-beta CD4-CD8+ T cells is observed in peripheral blood, spleen, thymus, and lymph nodes
|
immune system
|
N |
• humoral response to vesicular stomatitis virus challenge is normal; kinetics of immunoglobulin class switching and antibody levels are comparable to wild-type mice
|
|
|
• CD8+/CD4+ T cell ratio is lower than wild-type or Irf2-deficient mice during course of LCMV infection
|
|
|
• numbers are normal or slightly increased in thymi
|
|
|
• CD4+CD8- T cells are often but not always increased in number in homozygotes
|
|
|
• 10-fold reduction in TCR alpha-beta CD4-CD8+ T cells is observed in peripheral blood, spleen, thymus, and lymph nodes
|
|
|
• significantly reduced cytotoxic responses against LCMV-infected target cells are observed
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation
(1 available);
any
Irf1 mutation
(19 available)
|
|
|
cellular
|
N |
• apoptosis following UV-induced damage is similar in mutant primary hepatocytes from 6-10 week males and wild-type cells
• 6-12 hours after UV irradiation, hepatocytes arrest in at G1/S, similar to wild-type cells
|
|
|
• cultured hepatocytes from 6-10 week males show a defect in DNA repair in an assay in which repair of a UV-damaged reporter plasmid by wild-type and null hepatocytes; recovery of reporter activity by Irf1-deficient hepatocytes is significantly lower than that of wild-type or Trp53-deficient cells
|
homeostasis/metabolism
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation
(1 available);
any
Irf1 mutation
(19 available)
|
|
|
cardiovascular system
|
|
• 28 days after induction of flow cessation in the common carotid artery, a significant increase of neointima formation was observed proximal of the ligation suture in mutants compared to control wild-type mice
|
homeostasis/metabolism
Allelic
Composition |
Irf1tm1Mak/Irf1+
|
|
Genetic
Background |
either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2) |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation
(1 available);
any
Irf1 mutation
(19 available)
|
|
|
normal phenotype
|
|
• mice are viable and fertile, with no detectable abnormalities
|
neoplasm
|
|
• 44% develop tumors as compared to 7% of controls
|
|
|
• angiosarcomas observed most frequently
|
mortality/aging
|
|
• earlier tumor induced death
|
neoplasm
|
|
• 96% develop tumors by 299 days of age compared to 56% of mice only homozygous for Trp53tm1Sia
• greater frequency of multiple tumors
|
mortality/aging
|
|
• 50% of mice die by 45 weeks; survival is increased relative to MRL-Faslpr mice
|
immune system
|
N |
• TNF alpha production is not significantly different from Faslpr, Irf1-sufficient mice
|
|
|
• at 12 weeks, splenic CD4+CD25+ T cells are increased in percentage compared to wild-type MRL-Faslpr mice; percentage increases from 27.1% at 8 weeks to 40.3% at 26 weeks in wild-type mice, double mutants have 60.6% at 26 weeks
• 26 week old mice have a percentage of CD4+CD25+CD62L+ T cells (32.2%) compared to wild-type MRL-Faslpr mice (13.1%)
|
|
|
• mesangial cells from 8- and 26-week old mice show significantly less Il12 production than Faslpr, Irf1-sufficient cells upon stimulation with LPS and interferon gamma
|
|
|
• levels of anti-dsDNA IgG2a are significantly decreased relative to Faslpr, Irf1-sufficient mice
|
|
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
hematopoietic system
|
|
• at 12 weeks, splenic CD4+CD25+ T cells are increased in percentage compared to wild-type MRL-Faslpr mice; percentage increases from 27.1% at 8 weeks to 40.3% at 26 weeks in wild-type mice, double mutants have 60.6% at 26 weeks
• 26 week old mice have a percentage of CD4+CD25+CD62L+ T cells (32.2%) compared to wild-type MRL-Faslpr mice (13.1%)
|
renal/urinary system
|
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
homeostasis/metabolism
cellular
|
|
• in response to LPS + IFN gamma stimulation, mesangial cells show significantly lower activation than cells from MRL-Faslpr mice
|
integument
|
N |
• mice do not show characteristic signs of skin disease; at 26 weeks of age, 7/10 mice show no skin involvement, while 3 show minimal skin irritation, compared to 8/10 Faslpr, Irf1 sufficient mice displaying moderate to severe skin involvement
|
mortality/aging
|
|
• 50% of mice die by 52 weeks; survival is increased relative to MRL-Faslpr mice
|
renal/urinary system
|
|
• not significantly different from Faslpr, Irf1-null mice or Faslpr, Irf1-sufficient mice
|
|
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
hematopoietic system
|
|
• mice display similar T cell population profiles to Faslpr, Irf1-null mice
|
immune system
|
N |
• TNF alpha production is not significantly different Faslpr, Irf1-sufficient mice or Faslpr, Irf1-null mice
|
|
|
• mice display similar T cell population profiles to Faslpr, Irf1-null mice
|
|
|
• at 26 weeks of age, levels are significantly higher relative to Faslpr, Irf1-null mice
|
|
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
homeostasis/metabolism
integument
|
|
• mice display varying severity of skin irritation ranging from little or none to mild or moderate to severe
|
Analysis Tools